S&P 500 Industrials Sector SEC Filings — March 03, 2026

03-03-2026

Tonix Pharmaceuticals Holding Corp. (TNXP) received Nasdaq approval to uplist its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective at market open on March 3, 2026. This transition reflects compliance with higher financial and corporate governance standards, potentially boosting visibility, liquidity, and institutional investor access. CEO Seth Lederman described the uplisting as a key milestone to drive shareholder value.

• ·TONMYA is the first new fibromyalgia treatment in over 15 years.
• ·Company's 10-K for year ended December 31, 2024, filed March 18, 2025.

03-03-2026

Protagenic Therapeutics, Inc. appointed William (Bill) Nichols, Jr., age 51, as President effective February 3, 2026. Mr. Nichols brings senior commercial leadership experience from bluebird bio, Dova Pharmaceuticals (now Sobi), and Bristol-Myers Squibb. Compensation includes an annual base salary of $350,000, eligibility for a 40% target bonus, and an option grant equal to approximately 1.0% of the company's fully diluted shares.

• ·No arrangements or understandings with other persons for Mr. Nichols' selection as officer.
• ·No family relationships between Mr. Nichols and any directors or executive officers.
• ·No transactions involving Mr. Nichols requiring disclosure under Item 404(a) of Regulation S-K.

03-03-2026

Limbach Holdings, Inc. reported record FY2025 revenue of $646.8M, up 24.7% YoY from $518.8M, with ODR revenue surging 40.6% to $485.7M (75.1% of total) and adjusted EBITDA rising 28.4% to $81.8M; Q4 revenue hit a record $186.9M (+30.1% YoY). However, GCR revenue declined 7.0% YoY to $161.1M for the year and 13.0% to $41.9M in Q4, total gross margin fell to 26.2% from 27.8%, and ODR gross margin dropped to 26.7% due to the Pioneer Power acquisition. The company announced a $50M share repurchase program and provided 2026 guidance of $730M-$760M revenue and $90M-$94M adjusted EBITDA.

• ·Q4 2025 gross margin declined to 25.7% from 30.3% YoY; ODR gross margin fell to 25.1% from 32.1% due to Pioneer Power integration.
• ·FY2025 total organic revenue growth was 3.6%; ODR organic growth 17.0%.
• ·2026 guidance: Revenue $730M-$760M, Adjusted EBITDA $90M-$94M, ODR organic growth 9-12%, gross margin 26-27%.
• ·Acquisitions contributed $109.1M to FY2025 revenue growth.
• ·Net cash from operations: Q4 $28.1M (vs $19.3M), FY $45.7M (vs $36.8M).

03-03-2026

Karyopharm Therapeutics Inc. entered into a Second Amendment to its Credit and Guaranty Agreement and a Forbearance Agreement on February 27, 2026, allowing deferral of certain principal and interest payments until September 2026 and maintaining a $10.0M minimum liquidity covenant through October 10, 2026, conditioned on raising at least $25.0M in equity proceeds by June 10, 2026. This aims to extend the liquidity runway beyond Q2 2026 and anticipated top-line data from the Phase 3 XPORT-EC-042 trial in mid-2026. However, the agreements do not waive defaults, effectiveness depends on the capital raise, and the filing notes substantial doubt about the company's ability to continue as a going concern.

• ·Prepayment premium of 5% extended through June 10, 2026, or to May 8, 2027 if Capital Raise Trigger met
• ·Forbearance on payment defaults under 2028 Notes and 2029 Notes until September 30, 2026
• ·Forbearance on liquidity covenant defaults until October 10, 2026
• ·Annual Report on Form 10-K for year ended December 31, 2025 filed February 13, 2026

03-03-2026

SmartStop Self Storage REIT, Inc. disclosed same-store metrics for facilities stabilized since January 1, 2025 (excluding four properties), showing physical occupancy slightly down YoY to 92.1% as of December 31, 2025 (from 92.3%), up to 92.7% in January 2026 (from 92.1%), and flat at 92.7% in February 2026. However, monthly web rates declined YoY across all periods (e.g., -4.1% to $0.93 in Dec, -13.3% to $0.91 in Jan), as did move-in rates (e.g., -15% to $0.85 in Jan), while in-place rates were flat to slightly up (e.g., +0.6% to $1.65 in Feb). This provides a mixed operational picture with stable occupancy but softening new customer pricing.

• ·Same-store facilities defined as stabilized and comparable properties included in consolidated results since January 1, 2025.
• ·Disclosure furnished under Item 7.01, not deemed 'filed' for liability purposes.

03-03-2026

Chiron Real Estate LP (Issuer) and Chiron Real Estate Inc. (Parent), affiliates of Global Medical REIT Inc., entered into a Master Note and Guaranty Agreement dated March 2, 2026, with NYL Investors LLC and New York Life affiliates, establishing an uncommitted facility for issuing senior promissory notes in series with aggregate principal not exceeding the Available Facility Amount. Notes can be requested in minimum increments of $10M, with maturities and average lives up to 10 years, during an Issuance Period of up to three years. The facility provides flexible access to capital without current obligations or draws.

• ·Issuance Period extends until the earlier of the third anniversary of March 2, 2026, or other termination events.
• ·Individual Notes mature no more than 10 years from issuance date with average life no more than 10 years.
• ·Facility is explicitly uncommitted; New York Life has no obligation to purchase Notes or quote spreads.

03-03-2026

Atlantic Union Bankshares Corporation filed an 8-K on March 3, 2026, under Items 7.01 and 9.01, furnishing an updated investor handout (Exhibit 99.1) for use by management in meetings with investors, analysts, and other parties during Q1 2026. The handout is available on the company's Investor Relations website at https://investors.atlanticunionbank.com. No specific financial metrics or performance data were disclosed in the filing.

• ·Filing intended to satisfy Regulation FD Disclosure requirements.
• ·Securities registered on New York Stock Exchange: Common Stock (AUB) and Depositary Shares (AUB.PRA).

03-03-2026

Honeywell International Inc. announced on March 3, 2026, the filing of a Form 10 registration statement by its wholly owned subsidiary, Honeywell Aerospace Inc., with the SEC in connection with the anticipated spin-off of its Aerospace business into an independent, publicly traded company. A press release detailing the announcement is furnished as Exhibit 99.1. The filing includes extensive cautionary language on forward-looking statements, highlighting risks such as potential delays, failure to complete the Spin-Off, disruptions to operations, and uncertain financial impacts post-separation.

03-03-2026

Amylyx Pharmaceuticals reported Q4 and FY 2025 financial results, showing reduced R&D expenses of $21.2M (down 7% YoY) and $90.4M (down 13% YoY), SG&A expenses of $15.4M (down 10% YoY Q4) and $62.9M (down 45% YoY FY), and improved net losses of $33.0M (down 12% YoY Q4) and $144.7M (down 52% YoY FY), primarily due to lower spending on AMX0035 offset by avexitide development; however, product revenue was $0, down from $87.4M in FY2024. Cash position stood at $317M as of Dec 31, 2025, down from $344M at Q3 end but up from $177M at end-2024, providing runway into 2028. Pipeline progress includes completed recruitment for Phase 3 LUCIDITY trial of avexitide in PBH with topline data expected Q3 2026.

• ·Avexitide has FDA Breakthrough Therapy Designation for PBH and congenital HI, Orphan Drug Designation for hyperinsulinemic hypoglycemia.
• ·AMX0114 has FDA Fast Track Designation for ALS; Phase 1 LUMINA Cohort 1 (n=12) showed no treatment-related SAEs.
• ·IND-enabling studies for AMX0318 underway, targeting IND filing in 2027.
• ·Total assets $332.6M as of Dec 31, 2025 (up from $193.6M end-2024).

03-03-2026

ANI Pharmaceuticals, Inc. (ANIP) announced that President & CEO Nikhil Lalwani and members of the executive leadership team will present at the Raymond James & Associates’ 47th Annual Institutional Investors Conference in Orlando, Florida, on March 3, 2026. The company is providing an updated investor presentation (Exhibit 99.1) for use in meetings with investors and analysts. No specific financial metrics or performance data were disclosed in the filing.

• ·Presentation scheduled for March 3, 2026, at the Raymond James 47th Annual Institutional Investors Conference in Orlando, Florida.
• ·Investor presentation filed as Exhibit 99.1 under Item 9.01 and incorporated by reference under Item 7.01.

03-03-2026

Brookfield Asset Management Ltd. (BAM) filed an 8-K on March 3, 2026, under Items 8.01 and 9.01, disclosing the issuance of a press release dated March 3, 2026 (Exhibit 99.1). The filing contains no specific financial or operational details from the press release. No performance metrics, positive or negative, are reported.

• ·Securities registered: Class A Limited Voting Shares (BAM) on New York Stock Exchange
• ·Commission File Number: 001-41563
• ·I.R.S. Employer Identification No.: 98-1702516

03-03-2026

Advantage Solutions Inc. reported Q4 2025 revenues of $932.1M, up 4.5% YoY, driven by strong 21.6% growth in Experiential Services, but full-year revenues declined 0.7% to $3.54B amid 10.9% drop in Branded Services. Adjusted EBITDA decreased 7.3% to $87.7M in Q4 and 6.8% to $331.8M for the year, reflecting declines across Branded (down 29.1% Q4) and Retailer Services (down 22.5% Q4), partially offset by Experiential's 114.8% Q4 surge. The company ended with $241M cash (up ~$40M sequentially), ~$55M from divestitures, and anticipates flat to low-single-digit revenue growth and flat to down mid-single-digit Adjusted EBITDA in 2026.

• ·Net Leverage Ratio: 4.4x as of Dec 31, 2025
• ·FY 2026 Outlook: Adjusted Unlevered Free Cash Flow $250-275M; Net Interest Expense $160-170M; Capex $50-60M
• ·Conference call: March 3, 2026, 8:30 am EDT

03-03-2026

Destiny Media Technologies Inc. held its Annual General Meeting on February 27, 2026, where stockholders elected five directors—Frederick Vandenberg, Hyonmyong Cho, S. Jay Graber, David Summers, and David Mossberg—with For votes ranging from 83% to 89% and minimal withholdings. Proposal Two to ratify Davidson and Company LLP as the independent registered public accounting firm for the fiscal year ending August 31, 2026, passed overwhelmingly with 99.5% For votes and negligible opposition.

• ·Annual General Meeting held on February 27, 2026
• ·Filing date: March 3, 2026
• ·Auditor ratification for fiscal year ending August 31, 2026
• ·Exact For votes for Hyonmyong Cho: 3,304,968; Withheld: 416,587
• ·Exact For votes for S. Jay Graber and David Summers: 3,328,348 each; Withheld: 393,207 each
• ·Exact For votes for David Mossberg: 3,304,968; Withheld: 416,587

03-03-2026

908 Devices Inc. reported Q4 2025 revenue of $17.4M, up 21% YoY, and full-year 2025 revenue of $56.2M, up 18% YoY, with positive Adjusted EBITDA of $0.7M in Q4 but a full-year Adjusted EBITDA loss of $9.6M and net loss from continuing operations of $33.3M. Recurring revenue grew 22% YoY to $19.5M (35% of total), installed base expanded 24% to 3,736 devices, and cash position strengthened to $113.0M; however, GAAP gross margin remained flat at 51% for the full year. The company guides for 2026 revenue of $64.5M-$67.5M, implying 15-20% growth.

• ·OEM and funded partnership revenue: $1.0M in Q4 2025 (vs $0.7M Q4 2024); $3.0M FY 2025 (vs $1.6M FY 2024)
• ·Recurring revenue: 32% of Q4 2025 total revenue (vs 35% FY)
• ·Operating expenses Q4 2025: $6.1M (down from $23.4M Q4 2024 due to one-time items including goodwill impairment and contingent consideration changes)
• ·2026 revenue guidance: $64.5M to $67.5M

03-03-2026

Passage BIO, Inc. filed a Form 8-K on 2026-03-03 disclosing results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. This multi-item filing pertains to financial results with no specific revenue, earnings, or balance sheet metrics provided. No positive or negative performance indicators, guidance changes, or scheduled events were detailed.

03-03-2026

Target Corporation (TGT) reported fourth-quarter 2025 net sales of $30.5B, down 1.5% YoY from $30.9B, with comparable sales declining 2.5% due to a 3.9% drop in store sales partially offset by 1.9% digital growth, though Food & Beverage, Beauty, Toys, Essentials, and Home categories grew and non-merchandise sales rose over 25%. Full-year 2025 net sales decreased 1.7% to $104.8B from $106.6B, GAAP EPS fell to $8.13 from $8.86, and Adjusted EPS was $7.57 in line with expectations despite declines in operating income. For 2026, guidance calls for ~2% net sales growth, operating margin up ~20 bps to 4.8%, and EPS of $7.50-$8.50.

• ·Q4 gross margin rate improved to 26.6% from 26.2% YoY due to lower shrink and supply chain costs.
• ·Full-year SG&A expense rate flat at 20.6% YoY on a GAAP basis, but Adjusted rose to 20.9%.
• ·Net interest expense increased to $445M full-year from $411M due to higher debt levels.
• ·Cash provided by operating activities $6.6B full-year, down from $7.4B.
• ·Inventory decreased to $12.3B from $12.7B as of Jan 31, 2026.

03-03-2026

Golden Matrix Group, Inc. (GMGI) filed an 8-K on March 3, 2026, covering Items 3.03 (Material Impairments), 5.03 (Charter/Bylaws Amendments), 8.01 (Other Events), and 9.01 (Exhibits), marked as a Material Event with a subcategory of Charter/Bylaws Amendments. The filing, sized at 1 MB, provides no detailed financial metrics, period-over-period comparisons, or specific outcomes on impairments or amendments in the available EDGAR listing. No improvements or declines are quantifiable from the provided data.

• ·CIK: 0001437925
• ·SIC: 7372 (SERVICES-PREPACKAGED SOFTWARE)
• ·Fiscal Year End: December 31
• ·Business Address: 3651 Lindell Road, Ste D131, Las Vegas, NV 89103
• ·Acc-no: 0001477932-26-001129

03-03-2026

Adial Pharmaceuticals entered into a collaboration framework agreement with Molteni Farmaceutici for a proposed exclusive partnership on AD04 commercialization in Europe, expecting an upfront payment, milestone payments, tiered royalties (high single digits to low double digits), and nearly $60M in total potential aggregate value from royalties and milestones upon execution of a definitive agreement. However, the Special Meeting of Shareholders on February 26, 2026, failed to convene due to lack of quorum, necessitating additional meetings every 90 days to seek approval for issuing up to 13,823,512 shares underlying New Warrants. This development advances AD04's European pathway but underscores challenges in obtaining timely stockholder approval.

• ·Molteni granted exclusivity period for due diligence and planning.
• ·New patent filing could extend Loss of Exclusivity (LOE) from 2031 to 2045.
• ·Genetic screening simplified from blood draw to cheek swab.
• ·Inducement Agreement dated November 25, 2025, requires meetings every 90 days until approval or warrants expire.

03-03-2026

Hepion Pharmaceuticals, Inc. (OTCQB:HEPA) in-licensed a novel ctRNA biomarker assay from Cirna Diagnostics LLC for early diagnosis and surveillance of hepatocellular carcinoma (HCC) in high-risk cirrhosis patients, complementing its recently acquired mSEPT9 PCR-based assay as part of a strategic shift to liquid biopsy diagnostics. The ctRNA platform, validated across cohorts, offers earlier detection than DNA-based tests and potential expansion to other solid tumors. The global liquid biopsy market is valued at $10B, with the U.S. projected to reach nearly $9B by 2035, addressing current HCC surveillance that misses up to 75% of early-stage cancers.

• ·HCC represents 75-90% of liver cancer cases and is the sixth most common cancer worldwide, third deadliest globally.
• ·ctRNA assay detects mutant circulating tumor RNA for improved specificity in surveillance and early detection.

03-03-2026

PEDEVCO Corp. announced that its board of directors approved a 1-for-20 reverse stock split of its common stock. The reverse split is expected to become effective at 12:01 AM ET on March 13, 2026, with trading on a post-split basis beginning on the NYSE American at market open on the same day under the unchanged ticker 'PED' but with a new CUSIP number 70532Y402. No fractional shares will be issued; instead, holders will receive cash payments in lieu based on the closing price prior to the effective time.

• ·No change in trading symbol 'PED' post-split.
• ·Cash in lieu of fractional shares calculated as fraction multiplied by closing price on trading day before effective time.
• ·Information furnished under Item 7.01 is not 'filed' and not subject to liabilities under Section 18 of the Exchange Act.

03-03-2026

Emergent BioSolutions Inc. (NYSE: EBS) announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026, with him serving on the Audit and Finance Committee. Mr. Fowler brings over three decades of leadership in healthcare and financial services, including senior roles at Wells Fargo Securities, Deutsche Bank, JPMorgan, and Salomon Brothers. The appointment aims to support the company's ongoing turnaround, transformation, and strategic priorities in global health preparedness.

• ·Mr. Fowler previously served as president of Large Scale Biology Corporation, founding partner of Bio-Strategic Directors, and managing partner of Baycrest Capital.
• ·Mr. Fowler earned a Juris Doctor from University of Virginia School of Law, MBA from University of Virginia Darden School of Business, and BA in History from University of Virginia.
• ·Company has been operating for over 25 years in public health protection.

03-03-2026

Theravance Biopharma's Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint (OHSA Composite Score), leading to the program's wind down, while YUPELRI net sales grew 12% YoY to $266.6M in FY2025 and 6% YoY to $70.6M in Q4 2025. The company holds $326.5M cash at Q4 2025 (no debt), expects ~$400M by end-Q1 2026 including recent milestones, and anticipates $60-70M annualized cash flow from Q3 2026 after 60% cost reductions (~$70M savings from 2025's ~$110M opex). The Strategic Review Committee is accelerating evaluation of alternatives, including a potential sale, to maximize shareholder value.

• ·Restructuring impacts ~50% of workforce, including full R&D wind down and 50% G&A cut, over next two quarters.
• ·YUPELRI co-promotion: 65% profit/loss to Viatris, 35% to Theravance.
• ·TRELEGY milestones from Royalty Pharma triggered by GSK global net sales thresholds.
• ·$2.6B Irish tax attributes.
• ·Preliminary financials subject to change in upcoming 10-K.

03-03-2026

Aphoenity International Holdings Inc. (formerly Luduson G Inc., ticker LDSN) changed its domicile from Delaware to Wyoming via statutory conversion on July 21, 2025, with continuity of assets, liabilities, and securities. Effective October 1, 2025, the company name changed to Aphoenity International Holdings Inc., and on November 18, 2025, it implemented a 1,000-for-1 reverse stock split (with fractional shares rounded up) and updated its EIN to 98-1872097, while maintaining par value at $0.0001 per share.

• ·Trading symbol: LDSN (OTC)
• ·CIK: 0001737193
• ·SIC: 7374 (Services-Computer Processing & Data Preparation)
• ·Principal address: 35/F, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong
• ·Phone: +852 2824 8560

03-03-2026

Cullen/Frost Bankers, Inc. filed an 8-K/A on March 3, 2026, amending its February 11, 2026 8-K under Item 7.01 to replace the initial investor presentation with an updated version as of December 31, 2025. The revisions add information on the company's technology strategy, update peer data, and correct certain items from the original exhibit. No specific financial metrics or performance changes are disclosed in the filing.

• ·Presentation available at https://investor.frostbank.com
• ·References most recent 10-K filed February 5, 2026

03-03-2026

MainStreet Bancshares, Inc. announced on March 3, 2026, that it repurchased 174,280 shares of its common stock since the beginning of 2026 at an average price of $22.45 per share under its ongoing stock repurchase program, conducted in compliance with Rule 10b-18. This repurchase price was below the company's tangible book value of $25.52 per share as of December 31, 2025. The program does not obligate further repurchases and may be modified or terminated at any time.

• ·Repurchases conducted in accordance with Rule 10b-18 and other applicable legal requirements

03-03-2026

Global Arena Holding, Inc. (Parent) and its wholly-owned subsidiary Global Election Services, Inc. (GE Services) entered into an Asset Purchase Agreement dated February 26, 2026, with GES Acquisition Corp. and Easterly CV VI LLC, to sell substantially all assets of their technology-enabled election services business (including fixed assets, contracts, IP, receivables, and goodwill), excluding cash and certain other items. Consideration consists of $2.4M cash payable to GE Services and 2,571,428 shares of GES Acquisition common stock issued to Parent, with GES Acquisition assuming only specified post-closing liabilities. No financial performance metrics or period-over-period comparisons are provided in the agreement.

• ·Assets exclude cash, cash equivalents, tax returns, insurance policies, and non-assumed contracts.
• ·Assumed Liabilities limited to post-Effective Time obligations under Assumed Contracts, IP, and Permits.
• ·Exhibits include Certificate of Designations for Series A Convertible Preferred Stock, Promissory Note, Employment Agreements, NDA/IP Rights Agreement, and Bill of Sale.

03-03-2026

In ongoing receivership proceedings for Global Tech Industries Group, Inc. appointed on September 18, 2024, the court-approved receiver Paul L. Strickland finalized a confidential settlement agreement with former President and Director Kathy Griffin and family members on December 22, 2025, with court approval on February 26, 2026. Separately, the Company's wholly-owned subsidiary TTII Strategic Acquisitions & Equity Group Inc. obtained a default judgment against Astra Energy, Inc. on March 2, 2026, following a complaint filed on July 22, 2025. These legal resolutions address prior disputes but occur under court-supervised receivership, with no financial details disclosed.

• ·Receivership case: White Rocks (BVI) Holdings Inc., et al., v. Reichman, et al., Case No.: A-24-896359-B, Clark County, Nevada District Court
• ·Exhibits include Order 99.1 approving Griffin settlement and 99.2 for ASRE judgment

03-03-2026

TransCode Therapeutics, Inc. designated 1,214,204 shares of Series C Non-Voting Convertible Preferred Stock with a par value of $0.0001 per share, approved by the Board on February 27, 2026, as part of an Equity Issuance and Registration Rights Agreement with Unleash Immuno Oncolytics, Inc. dated March 2, 2026. The Series C shares are convertible 1:1 into Common Stock following stockholder approval per Nasdaq rules, with no general voting rights but protective provisions, and rank pari passu with Common Stock and Series A/B Preferred in liquidation. No dividends beyond those on Common Stock (as-if-converted), and includes a beneficial ownership limitation to prevent excessive ownership.

• ·Conversion effective after 5:00 p.m. ET on third Business Day post-stockholder approval.
• ·Holders entitled to same dividends as Common Stock on as-if-converted basis (excluding CVR Agreement rights).
• ·Beneficial Ownership Limitation prevents conversion if Holder would exceed calculated ownership threshold per Section 13(d).
• ·Liquidation treated pari passu with Common and Series A/B Non-Voting Preferred Stock.

03-03-2026

On March 3, 2026, BARK, Inc. filed an 8-K announcing that Matt Meeker, its Chief Executive Officer and Executive Chair of the Board, voluntarily withdrew from participation as a member in Great Dane Ventures, LLC. The announcement was made via a press release attached as Exhibit 99.1. No financial impacts or further details on implications were disclosed.

03-03-2026

On February 27, 2026, the Boards of Northpointe Bancshares, Inc. and its subsidiary Northpointe Bank received notices from directors R. Jeffrey Dean, Bruce L. Edger, and John M. Eggemeyer III of their intention to retire at the end of their current terms, expiring at the 2026 Annual Meeting of Stockholders, and they will not stand for reelection. Their decisions are not due to any disagreements with the Company on operations, policies, or practices. The Company expressed appreciation for their service, with Mr. Dean serving since 1999, Mr. Edger since 2005, and Mr. Eggemeyer since 2019.

• ·Mr. Dean serves on Audit Committee, Compensation Committee, and Corporate Governance and Nominating Committee.
• ·Mr. Edger serves on Compensation Committee and Corporate Governance and Nominating Committee.
• ·Mr. Eggemeyer serves on Audit Committee, Compensation Committee, and Corporate Governance and Nominating Committee.
• ·Directors will continue service through the 2026 Annual Meeting of Stockholders.

03-03-2026

China Pharma Holdings, Inc.'s (CPHI) wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd (Helpson), entered into a Technology Transfer Agreement on February 26, 2026, acquiring the Invention Patent for Prinsepia Utilis Esterol Sublingual Tablets and Method for Its Preparation (Patent No. 2018102273158) from Xiaoyan Zhang for $6.93M, payable in 12,600,000 restricted common shares at $0.55 per share. The agreement also includes technical services for product R&D, registration materials, and applications. Shares are issued under Regulation S exemption to a non-U.S. person.

• ·Patent No. 2018102273158, granted March 19, 2018, valid until March 19, 2038.
• ·Technical services include product R&D, registration materials preparation, and application filing.
• ·Issued under Regulation S exemption for offshore transaction to non-U.S. person.

03-03-2026

MIRA Pharmaceuticals completed dosing in its Phase 1 clinical trial of Ketamir-2, a proprietary selective oral NMDA receptor modulator, in 56 healthy volunteers across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, reporting no serious adverse events, dose-limiting toxicities, or clinically significant dissociative effects. The study, conducted at Hadassah Medical Center, evaluated SAD from 50 mg to 600 mg (32 participants) and MAD of 150 mg, 300 mg, or 600 mg daily for five days (24 participants). The company plans to submit for a Phase 2a proof-of-concept study in chemotherapy-induced peripheral neuropathy (CIPN) patients to the FDA in the first half of 2026.

• ·Study conducted at the Clinical Pharmacology Unit of Hadassah Medical Center in Jerusalem, Israel.
• ·Database lock, unblinding, and final pharmacokinetic/safety analyses underway.
• ·Plans to present Phase 1 data at an upcoming scientific meeting.
• ·No FDA-approved therapies specifically for CIPN; current management uses off-label agents or IV ketamine.

03-03-2026

Rigel Pharmaceuticals reported record Q4 2025 total revenues of $69.8 million (net product sales $65.4 million, +41% YoY from $46.5 million), driven by TAVALISSE ($45.6 million, +47%), GAVRETO ($10.2 million, +27%), and REZLIDHIA ($9.6 million, +29%); full-year revenues reached $294.3 million (net product sales $232.0 million, +60% YoY from $144.9 million) with TAVALISSE +52%, GAVRETO +146%, and REZLIDHIA +35%. However, total costs and expenses increased to $46.6 million in Q4 (+14% YoY) and $168.8 million for the year (+9% YoY), driven by higher R&D and personnel costs, though net income was $268.1 million in Q4 and $367.0 million for the year, boosted by a $245.9 million non-cash deferred tax benefit. The company anticipates 2026 total revenues of $275-290 million (net product sales $255-265 million) and positive net income.

• ·Enrollment ongoing in R289 Phase 1b dose expansion phase (up to 40 patients at 500 mg QD or BID); on track to complete enrollment and select Phase 2 dose in H2 2026, with preliminary data by end of 2026.
• ·R289 dose escalation: 33% (6/18) evaluable transfusion-dependent patients achieved RBC-TI ≥8 weeks at ≥500 mg QD.
• ·GAVRETO ARROW study: median OS 44.3 months overall, 62.4 months in US patients.
• ·Pralsetinib TAPISTRY study: ORR 67% (26/39) in RET fusion-positive solid tumors.
• ·FDA approved GAVRETO sNDA with boxed warning on Dec 22, 2025; met postmarketing commitment for AcceleRET-Lung.
• ·Michael P. Miller joined Board effective Feb 1, 2026.

03-03-2026

Valuence Merger Corp. I, a SPAC, entered into a convertible promissory note with VMCA Sponsor, LLC for principal up to $1.5M, interest-free, to fund operations prior to an initial business combination. The note matures on the earlier of the business combination closing or liquidation, with repayment limited to funds outside the trust account if no combination occurs, and is convertible at the payee's option into warrants at $1.50 each. No drawdowns have been specified, and the agreement includes standard trust waivers and no-prepayment terms.

• ·Note dated February 27, 2026
• ·Drawdowns funded within 1 business day of request, up to $1.5M total outstanding
• ·Conversion warrants identical to those issued in private placement at IPO
• ·Governed by New York law; no personal liability for Maker's officers/directors
• ·Payee waives claims against trust account

03-03-2026

Ward W. Woods informed Alphatec Holdings, Inc. of his retirement from the Board of Directors, effective February 27, 2026, for personal reasons with no disagreements on operations, policies, or practices; he also served on the Compensation Committee. In connection with his departure, the company entered a Vesting Acceleration Agreement fully vesting his unvested restricted stock units granted on June 11, 2025. The Board reduced its size from eight to seven directors on February 26, 2026.

• ·Vesting Acceleration Agreement filed as Exhibit 10.1
• ·Event reported on February 25, 2026; filing dated March 3, 2026

03-03-2026

Crinetics Pharmaceuticals, Inc. dismissed BDO USA, P.C. as its independent registered public accounting firm and appointed PricewaterhouseCoopers LLP (PwC) as the new firm on February 27, 2026, approved by the Audit Committee. BDO's reports on the fiscal years ended December 31, 2025 and 2024 contained no adverse opinions, qualifications, disagreements, or reportable events. BDO furnished a letter to the SEC dated March 3, 2026, agreeing with the company's statements.

• ·The company provided BDO's letter as Exhibit 16.1.
• ·No consultations with PwC occurred in fiscal years 2024-2025 or interim through February 27, 2026.

03-03-2026

On March 2, 2026, Covista Inc. (formerly Adtalem Global Education Inc.) amended its credit agreement to incur $510 million in new 2026 Term Loans maturing March 2, 2033, with interest rate margins reduced by 0.50% (Term SOFR + 2.25% with 0.75% floor or ABR + 1.25%). Proceeds refinanced existing term loans and fully redeemed $404.95 million in 5.50% Senior Secured Notes due 2028 at 100% of principal plus accrued interest, satisfying and discharging the related indenture. No declines or flat performance noted in this debt refinancing event.

• ·Redemption notice for Notes sent by Trustee on February 13, 2026.
• ·Original Credit Agreement dated August 12, 2021; Indenture dated March 1, 2021.
• ·2026 Term Loans mature on March 2, 2033.

03-03-2026

Black Rock Coffee Bar reported strong Q4 2025 results with total revenue of $53.6M, up 25.3% YoY, same store sales growth of 9.3%, and 12 new stores opened, driving operating income to $1.8M from a $0.1M loss and Adjusted EBITDA up 52.4% to $6.5M. For FY2025, revenue grew 24.5% to $200.3M with SSS up 10.1% and 32 new stores, but operating income declined sharply to $0.9M from $6.0M while net loss widened 130.1% to $16.5M amid higher SG&A expenses at 20.6% of revenue versus 15.7% prior year.

• ·Cash and cash equivalents $28.4M and total debt $26.7M as of Dec 31, 2025; repaid $30.1M under $50M term loan, leaving $19.9M outstanding.
• ·FY2026 outlook: 36 new store openings, total revenue $255-257M, mid-single digit SSS growth, Adjusted EBITDA $33.5-34.5M, CapEx $40-41M.
• ·Conference call on March 3, 2026 at 5:00 p.m. ET; replay available until March 17, 2026.

03-03-2026

Arbutus Biopharma and Genevant Sciences announced a $2.25B global settlement with Moderna resolving patent infringement claims over LNP technology used in COVID-19 vaccines, including $950M upfront payment in July 2026 and $1.3B contingent on a favorable appellate ruling on Section 1498. Moderna consents to judgment of infringement and no invalidity on four patents, receiving a global non-exclusive license. However, the $1.3B payment remains uncertain pending the appeal, and Pfizer/BioNTech litigation continues despite a favorable Markman ruling in September 2025.

• ·Arbutus evaluating return of capital to shareholders for Q3 2026 in conjunction with upfront payment.
• ·Roivant hosting investor conference call on March 3, 2026 at 4:45 p.m. ET.
• ·Pfizer/BioNTech litigation ongoing in the US following favorable Markman ruling in September 2025.

03-03-2026

ABVC BioPharma filed its 2025 Form 10-K on March 3, 2026, reporting total assets of $21.06 million as of December 31, 2025, a 179% YoY increase from $7.54 million in 2024, primarily driven by net property and equipment surging to $12.84 million from $0.51 million due to strategic land acquisitions in Taiwan. The company advanced its asset-backed licensing model by licensing CNS, oncology, and ophthalmology programs to subsidiaries AiBtl BioPharma, OncoX BioPharma, and ForSeeCon Eye Corporation, reducing direct clinical burn while retaining economics. No operating results or declines were highlighted, emphasizing balance sheet strengthening.

• ·Research institutions in network: Stanford University, University of California at San Francisco, Cedars-Sinai Medical Center
• ·Longtan land held by related party pending title transfer
• ·Puli land title transfer under government review as of press release date

03-03-2026

Delcath Systems, Inc. announced on March 3, 2026, the publication of CHOPIN clinical trial results in The Lancet Oncology via a press release furnished as Exhibit 99.1. The filing highlights this milestone under Item 8.01 Other Events, signed by CEO Gerard Michel. No financial or quantitative performance data was disclosed.

03-03-2026

Howmet Aerospace Inc. closed a $1.2B public notes offering on March 3, 2026, comprising $400M 3.750% notes due 2028, $300M 3.900% notes due 2029, and $500M 4.750% notes due 2036, with net proceeds plus $600M borrowings and cash on hand to fund the $1.8B purchase price for the Proposed CAM Acquisition from Stanley Black & Decker, Inc. The 2036 Notes are subject to special mandatory redemption at 101% of principal if the acquisition does not close by the Special Mandatory Redemption End Date under the December 22, 2025 Purchase Agreement. No period-over-period financial metrics are reported.

• ·Purchase Agreement dated December 22, 2025 between Stanley Black & Decker, Inc. and Howmet Aerospace Inc.
• ·Underwriting Agreement dated February 17, 2026.
• ·Interest payments: 2028 Notes semi-annually on March 3 and September 3 (commencing September 3, 2026); 2029 and 2036 Notes semi-annually on April 15 and October 15 (commencing October 15, 2026).
• ·Optional redemption prior to maturity at greater of 100% principal or discounted present value plus 10 bps (2028/2029 Notes) or 15 bps (2036 Notes).

03-03-2026

First Citizens BancShares, Inc. issued and sold $500M aggregate principal amount of its 4.869% Fixed-to-Floating Rate Senior Notes due 2032 on March 3, 2026, in a public offering. The notes were issued pursuant to a senior base indenture dated March 12, 2025, as supplemented, and an underwriting agreement dated February 25, 2026, with J.P. Morgan Securities LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC as representatives. No period-over-period financial comparisons are provided in the filing.

• ·Registration Statement on Form S-3 filed August 14, 2024 (File No. 333-281553)
• ·Prospectus Supplement dated February 25, 2026, filed February 26, 2026
• ·Senior Base Indenture dated March 12, 2025
• ·Second Supplemental Indenture dated March 3, 2026

03-03-2026

Bath & Body Works, Inc. issued a notice of redemption on March 3, 2026, for any and all outstanding 6.694% Senior Notes due 2027, with the redemption date set for April 10, 2026. The redemption price will be the greater of 100% of the principal amount or the present value of remaining scheduled payments discounted at the applicable treasury rate plus 50 basis points, plus accrued interest to the redemption date. No specific principal amount outstanding was disclosed in the filing.

• ·Common Stock: $0.50 par value, traded as BBWI on The New York Stock Exchange
• ·Company address: Three Limited Parkway, Columbus, OH 43230
• ·IRS Employer Identification No.: 31-1029810

03-03-2026

On February 25, 2026, the Compensation Committee of Target Hospitality Corp. adopted new forms of Executive Restricted Stock Unit (RSU) and Performance Stock Unit (PSU) Agreements under the 2019 Incentive Plan for awards to executive officers on or after that date, with terms substantially similar to prior versions. The Committee granted PSUs to three executives to motivate, incentivize, and retain them: Troy Schrenk (400,000 PSUs), Brendan Dowhaniuk (300,000 PSUs), and Heidi Lewis (175,000 PSUs). PSU vesting is based equally on Total Shareholder Return (TSR) and Adjusted EBITDA performance, ranging from 0% to 200% of target levels over the performance period.

• ·New RSU and PSU Agreements filed as Exhibits 10.1 and 10.2; specific PSU grant agreements as Exhibit 10.3.
• ·PSU Agreements similar to those filed in February 28, 2025 8-K (Exhibits 10.3, 10.4, 10.5, 10.6).

03-03-2026

On February 25, 2026, Babcock & Wilcox Enterprises, Inc. entered into the Tenth Amendment to its Credit Agreement originally dated January 18, 2024, which increases borrowing availability based on inventory and receivables, extends the maturity date to January 18, 2028, suspends the $3M PBGC Reserve (with re-imposition possible on January 1, 2027 if a $3M installment is not paid by September 15, 2026), modifies deposit account covenants, and releases BRC Group Holdings, Inc. as a guarantor. These changes improve liquidity and flexibility without any reported declines in terms. No prior period financial metrics are provided for comparison.

• ·Credit Agreement originally dated January 18, 2024
• ·Registrant address: 1200 EAST MARKET STREET, SUITE 650, AKRON, OHIO 44305
• ·Telephone: (330) 753-4511
• ·IRS Employer Identification No.: 47-2783641
• ·Commission File Number: 001-36876

03-03-2026

U.S. Physical Therapy, Inc. reported strong FY 2025 results with adjusted EBITDA up 16.1% YoY to $95M from $81.8M, net revenue up 16.3% (PT +16%, injury prevention +18%), and operating income +18.4%, despite 2.9% Medicare rate reductions. Q4 2025 adjusted EBITDA rose $3M YoY to $24.8M, PT revenues increased $20M to $173.8M, and visits per clinic per day hit a record 32.7 amid 11.2% total visit growth. Looking ahead, new hospital partnerships are expected to deliver at least $14M EBITDA lift in 2027 (USPH share >$7M post-minority interest) across 70 clinics.

• ·Seven consecutive quarters of record visits per clinic per day through Q4 2025.
• ·PT operating costs down $0.50 per visit in Q4 2025 YoY and up only 1.1% for FY 2025.
• ·Recent acquisitions: Pacific Northwest PT team, home care addition, injury prevention team strengthening NYC presence.
• ·Two new long-term hospital arrangements phasing in mid-2026 for 70 clinics.

03-03-2026

On February 26, 2026, the Compensation Committee of Anteris Technologies Global Corp. approved a one-time discretionary grant of restricted stock units (RSUs) valued at $500,000 to Chief Financial Officer Matthew McDonnell, effective March 4, 2026, under the company's Equity Incentive Plan. The RSUs vest one-third annually over three years, subject to continued employment, with accelerated vesting upon death, disability, or certain change in control events. This special award recognizes Mr. McDonnell's exemplary service and does not affect his target 2026 annual equity awards.

• ·RSUs to be determined by dividing $500,000 by the March 4, 2026 closing price of AVR common stock.
• ·Upon vesting, RSUs settle in CHESS depositary interests.
• ·Filing signed by Wayne Paterson on March 3, 2026.

03-03-2026

Fortitude Gold reported 2025 annual results with net sales declining 51% YoY to $18.4M from $37.3M, driven by sharply lower gold production of 5,236 oz (-68% YoY) and sales of 5,774 oz (-64% YoY), though higher realized gold prices of $3,235/oz (+37% YoY) provided some offset. All-in sustaining costs rose significantly to $1,697/oz (+76% YoY), cash balance dropped to $4.7M from $27.1M, and net income was a modest $0.4M versus a $2.0M loss in 2024. Subsequent events include a $12M private placement and a $40M East Camp Douglas joint venture with Hawthorne Land & Minerals.

• ·Ore mined 145,868 tonnes in 2025 (down from 447,304 tonnes in 2024); gold grade 0.39 g/t (down from 0.57 g/t).
• ·Total assets $136.2M at Dec 31 2025 (up from $122.1M); shareholders' equity $104.4M (down from $108.1M).
• ·Mine gross profit $10.0M in 2025 (down from $18.3M); 611 oz gold rounds/bullion inventory at year-end.
• ·Golden Mile Project permitting estimated Q2 2027; East Camp Douglas EA by H2 2026.

03-03-2026

Dave Inc. announced the commencement of a private offering of $150 million aggregate principal amount of Convertible Senior Notes due 2031, subject to market and other conditions, offered only to qualified institutional buyers under Rule 144A. Initial purchasers have an option to purchase up to an additional $22.5 million aggregate principal amount within a 13-day settlement period. In connection with the offering, the company expects to enter into privately negotiated capped call transactions with initial purchasers or affiliates.

• ·Notes offered in reliance on Rule 144A for qualified institutional buyers
• ·Option settlement period: 13 days beginning on issuance date
• ·Press release issued pursuant to Rule 135c under the Securities Act

03-03-2026

Community West Bancshares announced the retirement of Executive Vice President and Chief Operating Officer Blaine C. Lauhon, effective December 31, 2026, concluding his over 40-year banking career, including nearly a decade with the Bank since joining in 2017 via the Folsom Lake Bank acquisition. CEO James J. Kim highlighted Lauhon's leadership in operations, technology, and transformative initiatives, expressing gratitude for his contributions to the Bank's long-term success. No successor was named in the announcement.

• ·Lauhon named Chief Operating Officer in December 2024, Chief Administrative Officer in April 2024, Chief Banking Officer in 2021, Executive Vice President and Market Executive in 2019, and Senior Vice President and Senior Credit Officer in 2017.
• ·Bank headquartered in Fresno, California, established in 1979, first Banking Center opened January 10, 1980.
• ·Full board: Daniel J. Doyle (Chairman), Robert H. Bartlein (Vice Chairman), James J. Kim, Martin E. Plourd, Andriana D. Majarian, Suzanne M. Chadwick, Daniel N. Cunningham, Tom L. Dobyns, F.T. “Tommy” Elliott IV, Robert J. Flautt, James W. Lokey, Steven D. McDonald, Dorothea D. Silva, William S. Smittcamp, Kirk B. Stovesand; Louis C. McMurray (Director Emeritus).

03-03-2026

Rogers Corporation announced the departure of Michael Webb, its Senior Vice President and Chief Administrative Officer, effective March 13, 2026. Mr. Webb will receive severance payments and benefits under the Company’s Executive Severance Plan, contingent on executing a general release of claims and complying with restrictive covenants including non-competition and non-solicitation. The 8-K filing, dated March 3, 2026, was signed by Laura Russell, Senior Vice President, Chief Financial Officer, and Treasurer.

• ·Event reported date: March 2, 2026
• ·Filing date: March 3, 2026

03-03-2026

Cumberland Pharmaceuticals reported fourth quarter 2025 net revenues of $13.7 million, a 31% increase YoY, and full-year 2025 net revenues of $44.5 million, up 18% YoY, meeting their double-digit growth target. The company improved to adjusted earnings of $1.7 million for the year (up $2.7 million YoY) and generated $4.9 million in cash flow from operations (up $5.5 million YoY), while reducing debt by $10 million. However, it still posted a net loss of $2.9 million for 2025, an improvement of $3.6 million from the prior year.

• ·Vibativ approved in China (Feb 2025, exclusive with SciClone), launched in Saudi Arabia (Sep 2025, exclusive with Tabuk), approved in Mexico (Oct 2025, exclusive with PiSA).
• ·Co-commercialization agreement with RedHill Biopharma for Talicia (Oct 2025); Cumberland shares net revenues equally.
• ·Caldolor received permanent CMS J-code J1741 (Dec 2025) for reimbursement.
• ·Credit facility debt reduced by $10M from end of 2024.

03-03-2026

FingerMotion, Inc. held its Annual Meeting of Stockholders on February 26, 2026, with 27,126,232 shares (44.26% quorum of 61,281,308 outstanding shares) present; all proposals passed, including election of six directors with support from 82.56% (lowest for Yew Poh Leong) to 99.00%, auditor ratification at 98.86%, and advisory approval of executive compensation at 93.03%. Following the meeting, the Board re-appointed Martin Shen as President and CEO and Yew Hon Lee as CFO, Secretary, and Treasurer. Broker non-votes totaled 13,622,994 shares for director and compensation votes.

• ·Record date for AGM: January 14, 2026
• ·Fiscal year for auditor appointment: ending February 28, 2025
• ·News release issued: March 2, 2026 (Exhibit 99.1)
• ·17.44% withheld votes for Yew Poh Leong (highest withheld)